NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma
NCT04751877: Phase 3 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients IFM2020-05
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM
NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)